An interventional study of JenaValve Trilogy Heart Valve System in Aortic Regurgitation, Aortic Valve Insufficiency and Aortic Insufficiency, sponsored by JenaValve Technology, Inc.. Active, not recruiting at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by JenaValve Technology, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Aortic Valve Insufficiency with a site in United States — 7 open to participants now, 17 under way, none of them phase 3. Aortic Valve Insufficiency · United States.
Among the 41 studies in Aortic Valve Insufficiency with a site in United States, this one is the 20th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2024, is one of 22 with no phase, reaches primary completion later than 6 of the 16 other live ones, and was the 37th registered.
171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.
Browse Aortic Valve Insufficiency studies →7 of the 41 studies in Aortic Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18+
JenaValve Technology, Inc. · Sites in United States
The Cleveland Clinic · Sites in United States
Ages 18–90
Edwards Lifesciences · Sites in United States, Canada
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 3 started in 2024.
This study's enrollment of 50 is below the median of 123 across 92 interventional studies indexed under Aortic Valve Insufficiency.
Median enrollment 226 across the 24 interventional studies, 200 across the 17 observational. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 41 have an industry lead sponsor. The 10 most frequent:
JenaValve Technology, Inc. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
JenaValve Technology, Inc. has 6 studies filed under Aortic Valve Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Aortic Valve Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06608823JenaValve Technology, Inc.ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | 2027-06 |
| NCT04149600Beth Israel Deaconess Medical CenterIdentification of Genetic Causes of Calcific Aortic Valve Disease | 2027-06-30 |
| NCT05459233Institut universitaire de cardiologie et de pneumologie de Québec, University LavalValve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR | 2027-09-01 |
| NCT07197736Columbia UniversityDELINEATE-Prospective | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 41 studies in Aortic Valve Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and effectiveness of the JenaValve Trilogy™ Heart Valve System for transcatheter aortic valve replacement (TAVR) in subjects with continuous flow left ventricular assist devices (cfLVAD) and clinically significant aortic regurgitation (AR) who are indicated for TAVR
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects \>=18 years of age with continuous flow LVAD (cfLVAD) with AR1 leading to cfLVAD dysfunction using cfLVAD ASE guidelines that utilize contemporary management strategies for measurement of AR in patients with cfLVAD2,3:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transcatheter Aortic Valve Replacement (TAVR) TAVR in patients with continuous flow left ventricular assist devices (cfLVAD) and clinically significant aortic regurgitation (AR)
Device: JenaValve Trilogy Heart Valve System
TAVR with JenaValve Trilogy Heart Valve System
Primary Efficacy Endpoint: Modified VARC-3 Device Success
Device Success at 30 Days according to Valve Academic Research Consortium (VARC)-3 definition and modified for the LVAD population consisting of: - Freedom from all-cause mortality - Freedom from unsuccessful delivery of the device, and retrieval of the delivery system - Freedom from incorrect positioning of a single prosthetic heart valve into the proper anatomical location - Freedom from surgery or intervention related to the device or to a major vascular or access-related or cardiac structural complication - Intended performance of the valve (i.e., no moderate or severe prosthetic valve regurgitation)
Time frame: 30 days
Primary Safety Endpoint: VARC-3 Early Safety Composite
Consisting of: - Freedom from all-cause mortality - Freedom from all stroke - Freedom from VARC type 2-4 bleeding - Freedom from major vascular, access-related, or cardiac structural complication - Freedom from acute kidney injury stage 3 or 4 - Freedom from moderate or severe aortic regurgitation - Freedom from new permanent pacemaker due to procedure related conduction abnormalities - Freedom from surgery or intervention related to the device\* Consisting of: - Freedom from all-cause mortality - Freedom from all stroke - Freedom from VARC type 2-4 bleeding - Freedom from major vascular, access-related, or cardiac structural complication - Freedom from acute kidney injury stage 3 or 4 - Freedom from moderate or severe aortic regurgitation - Freedom from new permanent pacemaker due to procedure related conduction abnormalities - Freedom from surgery or intervention related to the device\*
Time frame: 30 days
Technical Success
Technical Success According to VARC-3 Definition
Time frame: At Exit From Procedure Room
Device Performance
Intended performance of the valve (i.e., no moderate or severe prosthetic valve regurgitation)\*
Time frame: 30 days and 1 year
Surgery/intervention related to device
Freedom from surgery or intervention related to the device# or to a major vascular or access-related or cardiac structural complication
Time frame: 30 days and 1 year
Bleeding
Freedom from VARC type 2-4 bleeding
Time frame: 30 days and 1 year
All Stroke
Number of patients that had stroke
Time frame: 30 days and 1 year
Acute Kidney Injury
Number of patients that had acute kidney injury (AKI) stage 3 or 4
Time frame: 7 days
Total aortic regurgitation
Number of patients that had moderate or severe total aortic regurgitation
Time frame: 30 days and 1 year
Major Vascular Complication
Number of patients that had major vascular, access-related, or cardiac structural complication
Time frame: 30 days and 1 year
Permanent pacemaker implantation
Number of patients that had these events
Time frame: 30 days
All-cause mortality
All-cause mortality
Time frame: 30 days and 1 year
Plan to share: No
Ran from Dec 2024 to primary completion in Aug 2026, 20 months.
Of 44 interventional studies with no phase under Aortic Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 74. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
JenaValve Technology, Inc.